Oxford-AstraZeneca vax shows early signs of efficacy, safety

July 20, 2020

Phase 1/phase 2 study data of the Oxford-AstraZeneca coronavirus vaccine showed a promising immune response in the 1,077 patients involved in the trials.

AstraZeneca became the latest to release early human trial data, publishing Interim results from the ongoing trial in The Lancet.

The COV001 trial is a blinded, multi-center, randomized controlled Phase I/II trial that assessed a single dose of AZD1222 against a meningitis vaccine. Ten participants also received two doses of AZD1222 one month apart. 

Early results confirmed a single dose of AZD1222 resulted in a four-fold increase in antibodies to the SARS-CoV-2 virus spike protein in 95% of participants one month after injection. In all participants, a T-cell response was induced, peaking by day 14, and maintained two months after injection. Neutralizing activity against SARS-CoV-2 was seen in 91% of participants one month after vaccination and in 100% of participants who received a second dose.

The early safety responses confirmed that reactions were similar to those of other adenoviral vector vaccines. They included temporary injection site pain and tenderness, mild-to-moderate headache, fatigue, chills, feverishness, malaise and muscle ache.

The vaccine, part of Operation Warp Speed, has already entered Phase 3 trials, aimed at proving its efficacy. 

Read the press release